Teleperformance (ENXTPA:TEP) is back in focus after Everest Group named the company a Leader in its Healthcare CXM Intelligent Operations PEAK Matrix Assessment, spotlighting Teleperformance’s AI powered healthcare customer experience capabilities.
See our latest analysis for Teleperformance.
Despite the recognition in healthcare CX, Teleperformance’s share price has been under pressure, with the year to date share price return down 14.01% and the 1 year total shareholder return down 34.33%, pointing to fading momentum even after a 2.26% 30 day share price gain.
If you are looking beyond Teleperformance and this healthcare AI story, it could be a useful moment to scan the market for 129 healthcare AI stocks
Teleperformance’s share price has struggled over 1 and 5 years despite fresh recognition for its healthcare AI operations. Does today’s valuation still offer a skewed payoff for new buyers, or has that window narrowed?
Most Popular Narrative: 27.5% Undervalued
The most followed narrative on Teleperformance compares a fair value of €74.86 with the last close at €54.26, framing the current gap through a long term cash flow lens anchored by a 9.8% discount rate.
The analysts have a consensus price target of €74.86 for Teleperformance based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €140.0, and the most bearish reporting a price target of just €44.0.
Want to see how relatively flat revenue assumptions still back a higher fair value? The key drivers are profit margins, earnings projections, and the future P/E that the narrative uses.
Result: Fair Value of €74.86 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Teleperformance narrative still hinges on reversing pressure in Specialized Services and managing foreign exchange headwinds. These factors have already weighed on reported profitability.
Find out about the key risks to this Teleperformance narrative.
Next Steps
Mixed signals here, with Teleperformance carrying both concerns and potential upside, so move quickly, review the data, and weigh the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Teleperformance?
If Teleperformance has your attention, do not stop here. Use the Simply Wall St Screener to spot other opportunities that could round out your portfolio.
- Target potential upside by scanning a curated list of companies that look attractively priced on quality and valuation using the 239 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies that combine higher yields with resilient profiles through the 464 dividend fortresses.
- Dial down portfolio risk by focusing on companies with sturdier financial profiles via the 293 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com